INDOCO2024-04-012024-06-30 INDOCO2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member INDOCO2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member INDOCO2024-06-30 INDOCO2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2024-04-01 2025-03-31 2024-07-23 2024-07-10 INR Lakhs First quarter 10:00:00 11:00:00 2024-07-23 2024-07-23 Not applicable Single segment Pharmaceutical 2024-04-01 2024-06-30 Unaudited Standalone 4014300000.00 35200000.00 4049500000.00 906500000.00 362300000.00 46700000.00 907800000.00 118800000.00 237000000.00 1275300000.00 3854400000.00 195100000.00 0.00 195100000.00 47300000.00 -1700000.00 45600000.00 0.00 149500000.00 0.00 0.00 0.00 0.00 149500000.00 -2200000.00 147300000.00 0.00 0.00 184400000.00 2 1.62 1.62 0.00 0.00 1.62 1.62 1. The unaudited Standalone Results for the Quarter ended 30th June, 2024, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 23rd July, 2024. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Qtr ended Qtr ended Qtr ended Year ended & Income 30-06-2024 31-03-2024 30-06-2023 31-03-2024 from Operations (Unaudited) (Audited) (Unaudited) (Audited) India 21,331 20,816 23,055 92,431 Outside India 18,091 22,698 18,264 83,764 -------------------------------------------------------------------------------------------------------------------------- Total : 39,422 43,514 41,319 1,76,195 ============================================================== 5. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2024. 6. Figures for the quarter ended 31.3.2024 and 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2023 (limited reviewed) and 31.12.2022 (limited reviewed). 7. (*) Exceptional items include consideration received Rs. 19.7 cr for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Other Expenses 1028400000.00 Research & Development Expenses 246900000.00 Items that will not be reclassified to profit & loss -3000000.00 -3000000.00 -800000.00 0.00